Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The vasodilatory beta-blockers.

Michala E Pedersen1, John R Cockcroft

  • 1Department of Cardiology, Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK.

Current Hypertension Reports
|August 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Gene Polymorphisms Predict Arterial Stiffness and Serum MGP Levels in Chronic Kidney Disease Patients.

Genes·2025
Same author

Phenotypes of Hypertension: Impact of Age and Sex on Hemodynamic Mechanisms.

Journal of the American Heart Association·2025
Same author

Dysregulation of lipid mediators in patients with frequent exacerbations of COPD.

ERJ open research·2025
Same author

May Measurement Month 2021: an analysis of blood pressure screening results from the UK and Republic of Ireland.

European heart journal supplements : journal of the European Society of Cardiology·2024
Same author

Pulsatility and flow patterns across macro- and microcirculatory arteries of continuous-flow left ventricular assist device patients.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2023
Same author

The Timed Up and Go test predicts frailty in patients with COPD.

NPJ primary care respiratory medicine·2022
Same journal

Neural Control of Tissue Perfusion: Emerging Evidence and Beyond.

Current hypertension reports·2026
Same journal

Correction to: Should Incretin Agonist-Based Drugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
Same journal

Intersection of Pediatric Hypertension and Cardiovascular-Kidney-Metabolic Disease.

Current hypertension reports·2026
Same journal

Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?

Current hypertension reports·2026
Same journal

Leveraging the Electronic Health Record to Identify and Manage Resistant Hypertension.

Current hypertension reports·2026
Same journal

Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?

Current hypertension reports·2026
See all related articles

Newer vasodilating beta-blockers may improve cardiovascular outcomes by reducing central aortic pressure more effectively than traditional beta-blockers like atenolol. These drugs offer hemodynamic benefits, potentially leading to better stroke and mortality reduction.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Beta-blockers are established treatments for hypertension and cardiovascular disease.
  • Clinical data suggest some beta-blockers (e.g., atenolol) may be less effective in reducing stroke and cardiovascular mortality compared to other antihypertensive classes, despite similar blood pressure reduction.

Purpose of the Study:

  • To explore the potential benefits of newer vasodilating beta-blockers in cardiovascular disease management.
  • To investigate the hemodynamic differences between vasodilating and nonvasodilating beta-blockers.

Main Methods:

  • Review of clinical trial data and hemodynamic profiles of various beta-blockers.
  • Comparison of effects on central aortic pressure, peripheral vascular resistance, cardiac output, and left ventricular function.
  • Analysis of vasodilating mechanisms (alpha(1)-receptor blockade, nitric oxide bioactivity).

Related Experiment Videos

Main Results:

  • Nonvasodilating beta-blockers (e.g., atenolol) may be less effective in reducing central aortic pressure, stroke, and cardiovascular mortality.
  • Vasodilating beta-blockers (carvedilol, labetalol, nebivolol) promote vasodilation and have favorable hemodynamic profiles.
  • These agents reduce peripheral vascular resistance while maintaining or improving cardiac output and left ventricular function, decreasing central aortic blood pressure.

Conclusions:

  • Vasodilating beta-blockers demonstrate beneficial hemodynamic effects, including reduced central aortic pressure, compared to conventional beta-blockers.
  • Further large-scale trials are necessary to confirm if these hemodynamic improvements translate to superior cardiovascular outcomes.